Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Felicia Di Gregorio"'
Autor:
G Pizzarelli, Felicia Di Gregorio, Francesca Carboni, Maria Antonietta Romeo, Salvatore Musumeci, Mariano Malaguarnera, A. Solinas, Domenico Pietro Paolo Gallisai
Publikováno v:
BioDrugs. 12:55-63
Objective: Our study was designed to evaluate the effects of 2 dosage schedules of recombinant interferon (IFN)-α (IFNα-2a and IFNα-2b) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in β-thalassaemic patients with chroni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef57f9a01e6ef56718f1e14aea4c7520
https://doi.org/10.2165/00063030-199912010-00006
https://doi.org/10.2165/00063030-199912010-00006
Autor:
Salvatore Leonardi, A. Sciotto, Felicia Di Gregorio, Salvatore Musumeci, Vincenzo Monte, Enrica Passero, Carmela Lauria, Giovanna Russo Mancuso, Clorinda Mazzarino, Graziella Malaponte
Publikováno v:
Acta Haematologica. 98:83-88
The variation of natural killer (NK) cell activity and lymphocyte subsets 20 h after a single test dose of alpha-IFN, was studied in 17 thalassemic patients with chronic hepatitis C. All patients had suspended the alpha-IFN therapy at least 12 months
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b2c00103eb70e4e4377245f43c183ce
https://doi.org/10.1159/000203603
https://doi.org/10.1159/000203603
Autor:
Alberto Morabito, R. Malizia, Domenico Giuseppe D'Ascola, Michele Rizzo, Paolo Cianciulli, Aroldo Rizzo, Giovanni Garozzo, Massimo Midiri, C. Ciaccio, A Mangiagli, Giovanni Quarta, Carmelo Magnano, Felicia Di Gregorio, Gennaro D'Amico, Marcello Capra, Aurelio Maggio
Publikováno v:
Blood cells, moleculesdiseases. 28(2)
Deferiprone has been suggested as an effective oral chelation therapy for thalassemia major. To assess its clinical efficacy, we compared deferiprone with deferoxamine in a large multicenter randomized clinical trial. One-hundred forty-four consecuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5426e9b76cbeb514a09d5ed54213a7e2
https://pubmed.ncbi.nlm.nih.gov/14757428
https://pubmed.ncbi.nlm.nih.gov/14757428
Autor:
G.V. Russo, Felicia Di Gregorio, Maria Antonietta Romeo, G. Pappalardo, P. Verzi, Caltabiano M
Publikováno v:
Annals of the New York Academy of Sciences. 612:546-548
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4030f9c2fc9cdde18b0d01e058dcea8a
https://doi.org/10.1111/j.1749-6632.1990.tb24362.x
https://doi.org/10.1111/j.1749-6632.1990.tb24362.x
Publikováno v:
Annals of the New York Academy of Sciences. 612:553-555
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0cb2b1e74bbd3799a88257ccf6bae0d
https://doi.org/10.1111/j.1749-6632.1990.tb24364.x
https://doi.org/10.1111/j.1749-6632.1990.tb24364.x
Chitotriosidase, a macrophage marker, which is extremely increased in plasma of Gaucher patients, was measured in patients with beta-thalassemia, an haematological disorder characterized by the genetic defect of beta-globin chains synthesis resulting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d2eda4c06c5b9a564d73bbc15fb54f
http://hdl.handle.net/20.500.11769/13134
http://hdl.handle.net/20.500.11769/13134
Autor:
Piero De Stefano, Felicia Di Gregorio, Maria Domenica Cappellini, Giuseppe Verlato, Maria Rita Gamberini, C. Melevendi, Antonio Piga, V. Sabato, Caterina Borgna-Pignatti, Simone Rugolotto
We studied survival and disease complications in 1,146 patients with thalassemia major, born from January 1, 1960 to December 31, 1987. At last follow-up, in March 1997, probability of survival to age 20 years was 89% and to age 25 years was 82% for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0205576f073fab246b84562d1297c2
http://hdl.handle.net/11562/4640
http://hdl.handle.net/11562/4640
Autor:
Felicia Di Gregorio, A. Sciotto, Grazia Malaponte, Enrica Passero, Gino Schilirog, Maria Clorinda Mazzarino, Giovanna Russo-Mancuso
Publikováno v:
Scopus-Elsevier
alpha-interferon (alpha-IFN) has been used to treat chronic non-A non-B hepatitis in thalassaemic patients with response rates from 45% to 83%. Unfortunately, treatment with alpha-IFN is associated with side-effects which have a negative effect on th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfd65d7113e9dfbb87e7ae891b279c9e
http://hdl.handle.net/20.500.11769/23320
http://hdl.handle.net/20.500.11769/23320
Publikováno v:
Journal of Allergy and Clinical Immunology. 97:127-128
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c305623228508a3fb2f02fccc3c52ca6
https://doi.org/10.1016/s0091-6749(96)70291-9
https://doi.org/10.1016/s0091-6749(96)70291-9
Publikováno v:
Annals of the New York Academy of Sciences. 612:527-528
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::289f26235184f0543e96ec6d9f5a62f4
https://doi.org/10.1111/j.1749-6632.1990.tb24354.x
https://doi.org/10.1111/j.1749-6632.1990.tb24354.x